Published in J Clin Invest on October 01, 1996
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs (1999) 4.32
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol (2012) 2.58
Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res (2010) 1.68
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res (2008) 1.63
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest (1997) 1.49
Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol (2016) 1.43
Activation of Rap1 promotes prostate cancer metastasis. Cancer Res (2009) 1.41
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia (2011) 1.28
Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med (2015) 1.27
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis (2004) 1.23
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res (2010) 1.21
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology (2012) 1.19
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest (2011) 1.17
Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res (2011) 1.15
Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II. Biomaterials (2015) 1.15
Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer (2008) 1.15
Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res (2012) 1.14
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One (2010) 1.12
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol (2007) 1.10
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood (2005) 1.09
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis (2007) 1.08
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06
Bone marrow microenvironment and tumor progression. Cancer Microenviron (2008) 1.04
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate (2008) 1.03
Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun (2010) 1.01
An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS (1999) 1.01
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer (2003) 1.01
A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS One (2010) 1.01
Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron (2011) 1.01
Microfabricated physical spatial gradients for investigating cell migration and invasion dynamics. PLoS One (2011) 1.00
Physiopathology of spine metastasis. Int J Surg Oncol (2011) 1.00
The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer (2003) 1.00
Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis (2004) 1.00
Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci U S A (2003) 0.99
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis (2004) 0.98
Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate (2011) 0.98
Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat (2007) 0.98
Tumor metastasis to bone. Arthritis Res Ther (2007) 0.98
Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res (2014) 0.97
Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis (2007) 0.95
Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem (2013) 0.95
An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One (2012) 0.95
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis (2006) 0.95
Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest (2014) 0.94
Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res (2001) 0.94
The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. PLoS One (2011) 0.94
Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing. Clin Exp Metastasis (2003) 0.92
Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): first experience. World J Nucl Med (2013) 0.92
Parathyroid hormone-related protein is not required for normal ductal or alveolar development in the post-natal mammary gland. PLoS One (2011) 0.92
The application of a murine bone bioreactor as a model of tumor: bone interaction. Clin Exp Metastasis (2006) 0.92
TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res (2011) 0.90
Calcium-sensing receptor stimulation induces nonselective cation channel activation in breast cancer cells. J Membr Biol (2006) 0.90
Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice. J Bone Miner Metab (2008) 0.89
P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption. PLoS One (2011) 0.89
DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest (2014) 0.89
The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? Int J Breast Cancer (2011) 0.89
The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89
Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence. Clin Med Case Rep (2008) 0.89
Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol (2009) 0.88
Regulation of breast cancer-induced bone lesions by β-catenin protein signaling. J Biol Chem (2011) 0.88
Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol (2013) 0.88
Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep (2011) 0.88
Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol (2014) 0.87
Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice. PLoS One (2013) 0.87
Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis (2014) 0.87
Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One (2012) 0.87
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
PTHrP gene expression in cancer: do all paths lead to Ets? Crit Rev Eukaryot Gene Expr (2005) 0.86
Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol (2012) 0.86
Cancer-associated muscle weakness: What's bone got to do with it? Bonekey Rep (2015) 0.86
Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest (2002) 0.86
A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clin Exp Metastasis (2008) 0.86
Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod (2012) 0.85
DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA. Breast Cancer Res Treat (2013) 0.85
Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron (2011) 0.85
Breast tumor cell lines from pleural effusions. J Natl Cancer Inst (1974) 5.39
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med (1980) 3.15
Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A (1987) 3.06
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem (1986) 2.50
Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest (1987) 2.41
A murine model of experimental metastasis to bone and bone marrow. Cancer Res (1988) 2.32
Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem (1987) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res (1991) 2.26
Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin Chem (1992) 1.86
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest (1995) 1.79
Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science (1987) 1.56
Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54
Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ (1991) 1.41
Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer (1992) 1.31
Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc (1986) 1.21
Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med (1989) 1.21
The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab (1993) 1.11
Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab (1991) 1.11
Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Mol Cell Endocrinol (1993) 1.07
Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J Bone Miner Res (1993) 0.98
Regulation of parathyroid hormone-related protein production in a human lung squamous cell carcinoma line. J Endocrinol (1994) 0.93
Effects of experimental conditions on the release of 45calcium from prelabeled fetal mouse long bones. Bone (1995) 0.89
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
On the relationship between autobiographical memory and perceptual learning. J Exp Psychol Gen (1981) 3.40
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest (1990) 2.92
Mineralisation defects with pamidronate therapy for Paget's disease. Lancet (1993) 2.76
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology (1988) 2.60
Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol (1987) 2.59
Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55
Two cis-acting elements in the 3' untranslated region of alpha-CaMKII regulate its dendritic targeting. Nat Neurosci (2000) 2.34
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res (1993) 2.24
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol (1998) 2.17
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol (1999) 2.14
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med (1974) 2.08
Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev (1997) 2.08
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
Hydrophobic barriers of lipid bilayer membranes formed by reduction of water penetration by alkyl chain unsaturation and cholesterol. Biochemistry (1994) 1.95
Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol (1986) 1.93
Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A (1993) 1.92
Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res (1989) 1.87
Peptide synthesis catalyzed by an antibody containing a binding site for variable amino acids. Science (1994) 1.85
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
Departmental libraries: curse or blessing? Bull Med Libr Assoc (1978) 1.84
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med (1987) 1.82
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest (1995) 1.79
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
Cancer and bone. Endocr Rev (1998) 1.77
Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis (1994) 1.76
Gastrointestinal perforation by chicken bones. Radiology (1979) 1.74
Anisotropic conductance at improper ferroelectric domain walls. Nat Mater (2012) 1.73
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. Proc Natl Acad Sci U S A (1986) 1.69
Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest (1995) 1.68
Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest (1999) 1.67
Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res (1986) 1.64
Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res (2001) 1.64
Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat (1994) 1.61
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood (2000) 1.59
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res (2001) 1.57
Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun (1989) 1.56
Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology (1991) 1.56
Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (1990) 1.55
Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem (1998) 1.54
The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow. J Clin Invest (1995) 1.53
Alteration of vitamin D metabolism in Mexican-Americans. J Bone Miner Res (1990) 1.53
A murine model of human myeloma bone disease. Bone (1997) 1.53
Expression of lymphocyte surface IgE does not require switch recombination. Nature (1982) 1.53
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest (1997) 1.52
Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene (2001) 1.51
Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int (1997) 1.51
Cardiac abnormalities in poisoning with tricyclic antidepressants. Br Med J (1969) 1.50
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest (1997) 1.49
Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest (1988) 1.48
Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am J Med (1978) 1.47
Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology (1987) 1.46
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (1984) 1.45
N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther (2012) 1.45
Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res (1994) 1.44
Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology (1987) 1.42
Direct stimulation of bone resorption by thyroid hormones. J Clin Invest (1976) 1.42
Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res (2000) 1.42
Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J Clin Invest (1986) 1.41
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood (1999) 1.40